Public Sector Pension Investment Board Takes $9.89 Million Position in ADMA Biologics, Inc. (NASDAQ:ADMA)

Public Sector Pension Investment Board bought a new position in ADMA Biologics, Inc. (NASDAQ:ADMA - Free Report) in the third quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The firm bought 494,500 shares of the biotechnology company's stock, valued at approximately $9,885,000. Public Sector Pension Investment Board owned about 0.21% of ADMA Biologics at the end of the most recent reporting period.

Other hedge funds have also recently made changes to their positions in the company. FORA Capital LLC purchased a new stake in shares of ADMA Biologics during the 3rd quarter valued at approximately $831,000. Healthcare of Ontario Pension Plan Trust Fund raised its holdings in ADMA Biologics by 13.9% during the 3rd quarter. Healthcare of Ontario Pension Plan Trust Fund now owns 658,900 shares of the biotechnology company's stock valued at $13,171,000 after acquiring an additional 80,400 shares during the period. BNP Paribas Financial Markets lifted its position in shares of ADMA Biologics by 12.8% during the third quarter. BNP Paribas Financial Markets now owns 750,788 shares of the biotechnology company's stock worth $15,008,000 after acquiring an additional 85,250 shares in the last quarter. FMR LLC boosted its holdings in shares of ADMA Biologics by 3.7% in the third quarter. FMR LLC now owns 1,944,831 shares of the biotechnology company's stock worth $38,877,000 after acquiring an additional 68,881 shares during the period. Finally, Bank of Montreal Can grew its position in shares of ADMA Biologics by 30.6% in the third quarter. Bank of Montreal Can now owns 2,086,322 shares of the biotechnology company's stock valued at $40,443,000 after purchasing an additional 489,320 shares in the last quarter. 75.68% of the stock is currently owned by institutional investors.

ADMA Biologics Price Performance

Shares of ADMA traded down $1.72 during trading hours on Friday, reaching $20.11. 4,002,265 shares of the company's stock traded hands, compared to its average volume of 3,622,850. ADMA Biologics, Inc. has a 12 month low of $3.60 and a 12 month high of $23.64. The company has a current ratio of 7.09, a quick ratio of 3.26 and a debt-to-equity ratio of 0.48. The stock has a market cap of $4.75 billion, a PE ratio of 71.82 and a beta of 0.64. The firm's 50 day simple moving average is $19.08 and its 200-day simple moving average is $15.31.

ADMA Biologics (NASDAQ:ADMA - Get Free Report) last announced its earnings results on Thursday, November 7th. The biotechnology company reported $0.15 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.13 by $0.02. The business had revenue of $119.84 million during the quarter, compared to analyst estimates of $107.25 million. ADMA Biologics had a net margin of 17.80% and a return on equity of 53.20%. During the same period in the previous year, the business posted $0.01 earnings per share. Equities analysts expect that ADMA Biologics, Inc. will post 0.52 EPS for the current year.

Insider Activity at ADMA Biologics

In other news, CFO Brad L. Tade sold 15,000 shares of the company's stock in a transaction dated Friday, November 22nd. The stock was sold at an average price of $21.15, for a total value of $317,250.00. Following the completion of the transaction, the chief financial officer now directly owns 199,433 shares in the company, valued at approximately $4,218,007.95. This represents a 7.00 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, Director Lawrence P. Guiheen sold 9,000 shares of the firm's stock in a transaction dated Monday, September 9th. The shares were sold at an average price of $18.47, for a total value of $166,230.00. Following the transaction, the director now directly owns 153,941 shares in the company, valued at approximately $2,843,290.27. This represents a 5.52 % decrease in their ownership of the stock. The disclosure for this sale can be found here. 3.70% of the stock is owned by insiders.

Wall Street Analyst Weigh In

Several research analysts have commented on ADMA shares. Cantor Fitzgerald restated an "overweight" rating and issued a $20.00 target price on shares of ADMA Biologics in a research note on Friday, September 20th. Raymond James boosted their price objective on shares of ADMA Biologics from $18.00 to $25.00 and gave the company a "strong-buy" rating in a research note on Friday, November 8th. Finally, HC Wainwright increased their target price on shares of ADMA Biologics from $18.00 to $26.00 and gave the stock a "buy" rating in a research note on Friday, November 8th.

ADMA Biologics Company Profile

ADMA Biologics, Inc, a biopharmaceutical company, engages in developing, manufacturing, and marketing specialty plasma-derived biologics for the treatment of immune deficiencies and infectious diseases in the United States and internationally. The company offers BIVIGAM, an intravenous immune globulin (IVIG) product indicated for the treatment of primary humoral immunodeficiency (PI); ASCENIV, an IVIG product for the treatment of PI; and Nabi-HB for the treatment of acute exposure to blood containing Hepatitis B surface antigen and other listed exposures to Hepatitis B.